NCT05289492TerminatedPhase 1
Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma
Study of EOS884448 Alone, and in Combination with Iberdomide with or Without Dexamethasone, in Participants with Relapsed or Refractory Multiple Myeloma
Source: ClinicalTrials.gov · Last updated 26 Oct 2024
Reason given: Company operational decision. Decision to stop study is not due to safety or efficacy concerns
Brief summary (registry, in English)
This is a multicenter, open-label, phase I/II clinical study, to assess the safety, tolerability, antitumor activity, pharmacokinetics and pharmacodynamics of EOS884448 (also known as EOS-448 or GSK4428859A), alone or in combination with iberdomide with and without dexamethasone in participants with relapsed/refractory multiple myeloma (RRMM).
- Status (registry)
- Terminated
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- First submitted
- 11 Mar 2022
- Start date
- 1 May 2022
- Primary completion date
- 29 Nov 2023
- Lead sponsor
- iTeos Therapeutics
- Diseases
- Multiple myeloma
- NCT number
- NCT05289492
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- All participants with history of life-threatening toxicity related to prior immune therapy.
Other illness
- All participants with known auto-immune disease
- All participants with active graft versus host disease after allogeneic stem cell transplantation.
- All participants with active infection requiring systemic therapy.
- All participants with hypersensitivity to any of the treatments.
Other
- All participants with non-secretory MM
- All participants with active, unstable cardiovascular function.
- All participants with any active gastrointestinal dysfunction that prevents the patient from swallowing tablets or interferes with absorption of study treatment.
Who the study is looking for
- All participants must have a documented diagnosis of relapse/refractory Multiple Myeloma and have measurable disease as defined per IMWG criteria.
- All participants must have received at least 3 prior lines of MM therapy with IMiD, PI and Anti-CD-38, and progressed on their last therapy (prior BCMA targeted therapy allowed).
- All participants must have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0,1or 2.
- All participants must have adequate organ function.
- Females of childbearing potential (FCBP) or male participant must agree to follow contraception requirements.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (13)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| ZNA Cadix | Antwerp | Belgium | Unknown status |
| Institut Jules Bordet | Brussels | Belgium | Unknown status |
| Universitaire Ziekenhuizen KU Leuven | Leuven | Belgium | Unknown status |
| Hospital Fundación Jimenez Diaz | Madrid | Spain | Unknown status |
| CHU Amiens | Amiens | France | Unknown status |
| Centre Hospitalier Universitaire de Nantes | Nantes | France | Unknown status |
| APHP - Hôpital Saint Antoine | Paris | France | Unknown status |
| CHU de Poitiers | Poitiers | France | Unknown status |
| CHU Toulouse | Toulouse | France | Unknown status |
| Banner MD Anderson | Gilbert | United States | Unknown status |
| Hackensack University Medical Center | Hackensack | United States | Unknown status |
| Eastern Connecticut Hematology & Oncology | Norwich | United States | Unknown status |
| Fred Hutchinson Cancer Center | Seattle | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.